智通财经APP讯，海普瑞(002399.SZ)发布2024年度业绩预告，预计全年归属于上市公司股东的净利润5.89亿元至7.11亿元，同比扭亏为盈。
报告期内，肝素产业链经营环境有所改善，市场需求逐步回升。公司积极落实品牌出海战略，发挥海内外营销网络布局优势，肝素制剂业务发展态势良好，主要产品依诺肝素钠制剂在欧洲、美国、中国及非欧美等市场的销量保持增长，全球市场占有率进一步提升。
报告期内，全球肝素API业务需求同比改善，中国肝素API的出口量较去年同期上升，但受上游原材料价格的下降等因素影响，2024年平均出口单价同比去年有较大的跌幅。公司坚持主攻成熟法规市场的策略，以产品竞争力为前提，极力维护API价格体系，取得了良好的成效，年内产品均价优于中国整体出口均价，同时获得销量增长，迭加成本下降等因素，本公司API业务整体表现同比有所改善。
公司CDMO业务延续复苏向好的节奏，报告期内公司持续巩固深化与现有客户的战略合作关系，积极探索开发新客户群，整合内部资源，加强多元化的商业能力，助力CDMO业务收入及盈利能力的提升。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.